LA
ONC

Lee Ainslie’s BeOne Medicines Ltd ONC Stock Holding History

Lee Ainslie’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,529
Closed -$1.21M – 829
2021
Q2 		$1.21M Buy
3,529
+66
+2% +$21.9K 0.01% 243
2021
Q1 		$1.21M Buy
+3,463
New +$1.15M 0.01% 217

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Lee Ainslie's ONC Position: Q3 2021 in Review

Lee Ainslie sold out of BeOne Medicines Ltd (ONC) in Q3 2021, closing a stake of 3,529 shares — an estimated $1.21M sold.

Lee Ainslie first reported a position in ONC in Q1 2021 and held it in 2 quarters. The position peaked at $1.21M in Q2 2021. 254 funds tracked by Wall St. Rank hold ONC as of Q3 2021.

  • Lee Ainslie reported no remaining BeOne Medicines Ltd position as of Q3 2021 after selling out during the quarter.
  • Lee Ainslie sold 3,529 BeOne Medicines Ltd shares in Q3 2021, an estimated $1.21M.
  • Lee Ainslie first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 2 quarters.
  • Lee Ainslie's BeOne Medicines Ltd position peaked at $1.21M in Q2 2021.
  • 254 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.